Roche offers to buy out Genentech for $43.7 billion
Swiss drugmaker Roche Holding AG offered to acquire all outstanding shares in its US partner Genentech Inc for $43.7 billion.
Roche expects the combination to generate annual pre-tax cost synergies of about $750 million - $850 million and to be accretive to earnings per share in the first year after closing.
Roche confirmed its 2008 sales and earnings per share forecast and said it was still committed to increasing its dividend pay-out ratio for the next three years.
Roche also said its H1 net profit fell 2% to CHF 5.73 billion ($5.62 billion), hit by loss of sales of influenza drug Tamiflu and the weak US dollar. (Reuters)
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.